
Target action date for FDA decision is due on 15 November

Review begins for potential schizophrenia and bipolar I disorder drug

Shares rocketed following the announcement

Indivior’s Gilles Picard charts a path to greater patient access and new therapies

Value leaps to more than $1bn following mid-stage trial results

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

Early stage studies look positive for schizophrenia drug
Collaborates with Mindstrong Health on mental health research

But will keep testing the candidate in schizophrenia

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

The former RB pharma unit hopes for sales in the $1bn region